×
About 6,546,368 results

ALLMedicine™ Detailed topics Center - Clinicaltrials.gov

Hemorrhagic Stroke in Setting of Severe COVID-19 Infection Requiring Extracorporeal Membrane Oxygenation (ECMO)
https://www.sciencedirect.com/science/article/pii/S1052305720304341

To highlight the increased risk of hemorrhagic stroke secondary to postulated COVID-19 mediated vasculopathy with concomitant ECMO related bleeding complications.

Assessment of patients who tested positive for COVID-19 after recovery
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30433-3/fulltext

Since the start of the outbreak in December 2019, COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), has led to an increasing number of infections worldwide, with an estimated overall mortality of 5·7%.1 Meanwhile, many patients who were hospitalised have recovered and were discharged to self-quarantine. However, some patients have tested positive for COVID-19 aga...

Kinetics of viral load and antibody response in relation to COVID-19 severity
https://dm5migu4zj3pb.cloudfront.net/manuscripts/138000/138759/cache/138759.1-20200701111152-covered-253bed37ca4c1ab43d105aefdf7b5536.pdf

The SARS-CoV-2 is the causative agent for COVID-19 pneumonia. Little is known about the 60 kinetics, tissue distribution, cross-reactivity and neutralization antibody response in COVID61 19 patients. Two groups of RT-PCR confirmed COVID-19 patients were enrolled in this study, 62 including 12 severe patients in ICUs who needed mechanical ventilation and 11 mild patients 63 in isolation wards...

Liver injury in COVID-19: management and challenges
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30057-1/fulltext

In December, 2019, an outbreak of a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], previously 2019-nCoV) started in Wuhan, China, and has since become a global threat to human health. The number of confirmed cases of 2019 coronavirus disease (COVID-19) has reached 87 137 worldwide as of March 1, 2020, according to WHO COVID-19 situation report 41; most of the...

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper
https://www.sciencedirect.com/science/article/pii/S2589555920300471

The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropria...

Surgeons' response to COVID ‐19: modified workflow to adapt to the new normal
https://bjssjournals.onlinelibrary.wiley.com/doi/10.1002/bjs.11773

An optimized workflow is mandatory to restore surgical care to the population in the ‘new‐normal’ of COVID‐19 pandemic1-3. Our hospital was the largest tertiary centre in Beijing that continued to provide full‐ranged surgical care from January 26 through April 29. We have received 99 809 surgical outpatients and 4376 emergencies, and 5378 surgeries have been performed. We herein introduce our m...

Adaptive immunity to SARS-CoV-2
https://academic.oup.com/ooim/article/doi/10.1093/oxfimm/iqaa003/5869360?searchresult=1

The majority of SARS-CoV-2 exposed individuals mount an antibody response within around 2-weeks and spike antigen binding responses correlate well with functional virus neutralisation. A minority make little detectable antibody, generally those with either very mild/asymptomatic disease or those with severe/lethal infection. However, in general, antibody titre correlates with viral load and dur...

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
https://www.nature.com/articles/s41577-020-0389-z

T cell reactivity against SARS-CoV-2 was observed in unexposed people; however, the source and clinical relevance of the reactivity remains unknown. It is speculated that this reflects T cell memory to circulating ‘common cold’ coronaviruses. It will be important to define specificities of these T cells and assess their association with COVID-19 disease severity and vaccine responses.

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
https://link.springer.com/article/10.1007/s00406-019-00982-6
European Archives of Psychiatry and Clinical Neuroscience;

Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is limited in ...

Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700135/
Scientific Reports;

Chronic levodopa treatment leads to the appearance of dyskinesia in the majority of Parkinson’s disease patients. Neurovascular dysregulation in putaminal and pallidal regions is thought to be an underlying feature of this complication of treatment. We used microPET to study unilaterally lesioned 6-hydroxydopamine rats that developed levodopa-induced abnormal involuntary movements (AIMs) after ...

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283839/
NPJ Parkinson's Disease;

IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson’s disease (PD). The primary objective was to investigate the safety and tolerability of IRL790 in PD patients with LID in a randomized controll...

Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson’s disease
https://www.degruyter.com/view/journals/revneuro/27/7/article-p729.xml
Reviews in the Neurosciences;

Parkinson’s disease (PD) is primarily a motor disorder that involves the gradual loss of motor function. Symptoms are observed initially in the extremities, such as hands and arms, while advanced stages of the disease can effect blinking, swallowing, speaking, and breathing. PD is a neurodegenerative disease, with dopaminergic neuronal loss occurring in the substantia nigra pars compacta, thus ...

Dysfunctional inhibitory control in Parkinson’s disease patients with levodopa-induced dyskinesias
https://link.springer.com/article/10.1007/s00415-018-8945-1
Journal of Neurology;

Chronic dopamine replacement therapies in Parkinson’s disease can induce side effects, such as levodopa-induced dyskinesias and impulse control disorders. A dysfunction of inhibitory brain networks has been related to both disorders; however, there is no clear behavioral evidence supporting this hypothesis. We aimed to determine whether PD patients with levodopa-induced dyskinesias show feature...

Researchers gain insight into factors influencing immunotherapy response in kidney cancer
https://www.healio.com/news/hematology-oncology/20200710/researchers-gain-insight-into-factors-influencing-immunotherapy-response-in-kidney-cancer

Jul 9th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 6th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma
https://www.healio.com/news/hematology-oncology/20200708/retreatment-with-cart-therapy-shows-clinical-efficacy-in-lymphoma

Jul 7th, 2020 - In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Dual target CAR T-cell therapy effective, durable, less toxic in lymphoma
https://www.healio.com/news/hematology-oncology/20200706/dual-target-car-tcell-therapy-effective-durable-less-toxic-in-lymphoma

Jul 5th, 2020 - A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.

Herpes Zoster Ophthalmicus
https://www.aao.org/eyenet/article/herpes-zoster-ophthalmicus-pearls

Herpes zoster (HZ), or shingles, results from reactivation of latent infection with varicella- zoster virus, which also causes chicken­pox. Anyone who has had chickenpox, even in subclinical form, is at risk for developing HZ. It is estimated that the lifetime risk of HZ is 30%, and 1 mil­lion new cases are reported annually in the United States.1 An effective shingles vaccine has been approved...